{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:16:29Z","timestamp":1793999789930,"version":"4.8.0"},"reference-count":41,"publisher":"Portland Press Ltd.","issue":"11","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,6,14]]},"abstract":"<jats:p>Patients with hyperthyroidism exhibit increased risk of development and progression of cardiac diseases. The activation of the renin\u2013angiotensin system (RAS) has been indirectly implicated in these cardiac effects observed in hyperthyroidism. Angiotensin-(1\u20137) (Ang-(1\u20137)) has previously been shown to counterbalance pathological effects of angiotensin II (Ang II). The aim of the present study was to investigate the effects of elevated circulating Ang-(1\u20137) levels on cardiac effects promoted by hyperthyroidism in a transgenic rat (TG) model that constitutively overexpresses an Ang-(1\u20137)-producing fusion protein [TGR(A1-7)3292]. TG and wild-type (WT) rats received daily injections (i.p.) of triiodothyronine (T3; 7 \u00b5g\/100 g of body weight (BW)) or vehicle for 14 days. In contrast with WT rats, the TG rats did not develop cardiac hypertrophy after T3 treatment. Indeed, TG rats displayed reduced systolic blood pressure (SBP) and cardiac hyperdynamic condition induced by hyperthyroidism. Moreover, increased plasma levels of Ang II observed in hyperthyroid WT rats were prevented in TG rats. TG rats were protected from glycogen synthase kinase 3\u03b2 (GSK3\u03b2) inactivation and nuclear factor of activated T cells (NFAT) nuclear accumulation induced by T3. In vitro studies evidenced that Ang-(1\u20137) prevented cardiomyocyte hypertrophy and GSK3\u03b2 inactivation induced by T3. Taken together, these data reveal an important cardioprotective action of Ang-(1\u20137) in experimental model of hyperthyroidism.<\/jats:p>","DOI":"10.1042\/cs20171606","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T14:25:14Z","timestamp":1524493514000},"page":"1117-1133","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Angiotensin-(1\u20137) reduces cardiac effects of thyroid hormone by GSK3\u0392\/NFATc3 signaling pathway"],"prefix":"10.1042","volume":"132","author":[{"given":"Nathalia","family":"Senger","sequence":"first","affiliation":[{"name":"Department of Anatomy, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos\u00a0Barrouin","family":"Melo","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela\u00a0Placon\u00e1","family":"Diniz","sequence":"additional","affiliation":[{"name":"Department of Anatomy, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria\u00a0Jos\u00e9","family":"Campagnole-Santos","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robson Augusto Souza","family":"Santos","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luiza\u00a0M.","family":"Barreto-Chaves","sequence":"additional","affiliation":[{"name":"Department of Anatomy, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2018,6,5]]},"reference":[{"key":"2021113010580712000_B1","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S2213-8587(14)70225-6","article-title":"Iodine deficiency and thyroid disorders","volume":"3","author":"Zimmermann","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2021113010580712000_B2","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1524-6175.2006.05180.x","article-title":"Hyperthyroidism: a secondary cause of isolated systolic hypertension","volume":"8","author":"Prisant","year":"2006","journal-title":"J. Clin. Hypertens."},{"key":"2021113010580712000_B3","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1210\/er.2003-0033","article-title":"Thyroid hormone action in the heart","volume":"26","author":"Kahaly","year":"2005","journal-title":"Endocr. Rev."},{"key":"2021113010580712000_B4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJM200102153440707","article-title":"Thyroid hormone and the cardiovascular system","volume":"344","author":"Klein","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"2021113010580712000_B5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1210\/mend-5-4-542","article-title":"Effects of varying the position of thyroid hormone response elements within the rat growth hormone promoter: implications for positive and negative regulation by 3,5,30-triiodothyronine","volume":"5","author":"Brent","year":"1991","journal-title":"Mol. Endocrinol."},{"key":"2021113010580712000_B6","first-page":"38","article-title":"Molecular basis oh physiological heart growth: fundamental concepts and new players","volume":"14","author":"Maillet","year":"2013","journal-title":"Nature"},{"key":"2021113010580712000_B7","first-page":"R1473","article-title":"Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling","volume":"285","author":"Hu","year":"2003","journal-title":"Am. J. Physiol."},{"key":"2021113010580712000_B8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00395-010-0089-0","article-title":"Blockage of angiotensin II type 2 receptor prevents thyroxine-mediated cardiac hypertrophy by blocking Akt activation","volume":"105","author":"Carneiro-Ramos","year":"2010","journal-title":"Basic Res. Cardiol."},{"key":"2021113010580712000_B9","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00395-009-0043-1","article-title":"Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hyperthophy through the Akt\/GSK-3beta\/mTOR signaling pathway","volume":"104","author":"Diniz","year":"2009","journal-title":"Basic Res. Cardiol."},{"key":"2021113010580712000_B10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1161\/01.HYP.31.1.356","article-title":"Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system","volume":"31","author":"Iyer","year":"1998","journal-title":"Hypertension"},{"key":"2021113010580712000_B11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1161\/01.HYP.36.3.417","article-title":"Contribution of angiotensin-(1-7) to blood pressure regulation in salt-depleted hypertensive rats","volume":"36","author":"Iyer","year":"2000","journal-title":"Hypertension"},{"key":"2021113010580712000_B12","doi-asserted-by":"publisher","first-page":"H980","DOI":"10.1152\/ajpheart.00768.2016","article-title":"Angiotensin (1-7) attenuates angiotensin II-induced cardiac hypertrophy via a Sirt3-dependent mechanism","volume":"312","author":"Guo","year":"2017","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113010580712000_B13","first-page":"H1560","article-title":"Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor","volume":"289","author":"Tallant","year":"2005","journal-title":"Am. J. Physiol."},{"key":"2021113010580712000_B14","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1161\/01.HYP.0000160325.59323.b8","article-title":"Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptor in conscious rats","volume":"45","author":"Walter","year":"2005","journal-title":"Hypertension"},{"key":"2021113010580712000_B15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bph.13742","article-title":"Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22","volume":"174","author":"Karnik","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"2021113010580712000_B16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/HYPERTENSIONAHA.116.07572","article-title":"G-Protein-couple receptor MrgD is a receptor for angiotensin-(1-7) involving adenyly cyclase, cAMP, and phosphokinase A","volume":"68","author":"Tetzner","year":"2016","journal-title":"Hypertension"},{"key":"2021113010580712000_B17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ejphar.2008.05.024","article-title":"The Angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats","volume":"590","author":"Ebermann","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"2021113010580712000_B18","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1111\/bph.13225","article-title":"Angiotensin-(1-7) administration benefits cardiac, renal and progenitor cell function in db\/db mice","volume":"172","author":"Papinska","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"2021113010580712000_B19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.phrs.2012.05.001","article-title":"Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes","volume":"66","author":"Yousif","year":"2012","journal-title":"Pharmacol. Res."},{"key":"2021113010580712000_B20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1152\/physiolgenomics.00227.2003","article-title":"Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats","volume":"17","author":"Santos","year":"2004","journal-title":"Physiol. Genom."},{"key":"2021113010580712000_B21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10557-013-6473-x","article-title":"Angiotensin II Type 2 receptor (ATR2) is associated with increased tolerance of the hyperthyroid heart to ischemia-reperfusion","volume":"27","author":"Tavares","year":"2013","journal-title":"Cardiovasc. Drugs Ther."},{"key":"2021113010580712000_B22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1161\/HYPERTENSIONAHA.114.04893","article-title":"Beneficial effects of angiotensin-(1-7) againts deoxyxorticosterone acetate-induced diastolic dysfunction occur independently of changes in blood pressure","volume":"66","author":"Almeida","year":"2015","journal-title":"Hypertension"},{"key":"2021113010580712000_B23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neuropharm.2015.04.036","article-title":"Activation of angiotensin-(1-7)\/Mas axis in the brain lowers blood pressure an attenuates cardiac remodeling in hypertensive transgenic (mRen2)27rats","volume":"97","author":"Kangussu","year":"2015","journal-title":"Neuropharmacology"},{"key":"2021113010580712000_B24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/0196-9781(94)90103-1","article-title":"Plasma angiotensin-(1-7) immunoreactivity is increased by salt load, water deprivation, and hemorrhage","volume":"15","author":"Botelho","year":"1994","journal-title":"Peptides"},{"key":"2021113010580712000_B25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"2021113010580712000_B26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1161\/HYPERTENSIONAHA.109.143255","article-title":"Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide\/guanosine 3\u20325\u2032-cyclicmonophosphate-dependent pathway","volume":"55","author":"Gomes","year":"2010","journal-title":"Hypertension"},{"key":"2021113010580712000_B27","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1016\/j.peptides.2006.04.015","article-title":"Tissue-specific modulation of angiotensin-converting enzyme (ACE) in hyperthyroidism","volume":"27","author":"Carneiro-Ramos","year":"2006","journal-title":"Peptides"},{"key":"2021113010580712000_B28","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/1753944715623228","article-title":"Cardiac ACE2\/angiotensin 1-7\/Mas receptor axis is activated in thyroid hormone-induced cardiac hypertrophy","volume":"10","author":"Diniz","year":"2015","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"2021113010580712000_B29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1053\/j.ctsap.2005.12.004","article-title":"Medical management of hyperthyroidism","volume":"21","author":"Trepaneir","year":"2006","journal-title":"Clin. Tech. Small Anim. Pract."},{"key":"2021113010580712000_B30","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1161\/01.HYP.38.3.665","article-title":"Angiotensin-(1-7): cardioprotective effect in myocardial ischemia\/reperfusion","volume":"38","author":"Ferreira","year":"2001","journal-title":"Hypertension"},{"key":"2021113010580712000_B31","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"key":"2021113010580712000_B32","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.peptides.2009.06.008","article-title":"Acute modulation of myocardial function by angiotensin 1-7","volume":"30","author":"Castro-Chaves","year":"2009","journal-title":"Peptides"},{"key":"2021113010580712000_B33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jash.2008.04.012","article-title":"Reduced isoproterenol-induced renin-angiotensin changes and extracellular matrix deposition in hearts of TG(A1-7)3292","volume":"2","author":"Nadu","year":"2008","journal-title":"J. Am. Soc. Hypertens."},{"key":"2021113010580712000_B34","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1089\/105072502760143809","article-title":"Cellular action of thyroid hormone on the heart","volume":"12","author":"Dilmann","year":"2002","journal-title":"Thyroid"},{"key":"2021113010580712000_B35","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00109-017-1511-y","article-title":"S100A8\/MYD88\/NF-kB: a novel pathway involved in cradiomyocyte hypertrophy driven by thyroid hormone","volume":"95","author":"Takano","year":"2017","journal-title":"J. Mol. Med."},{"key":"2021113010580712000_B36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0092-8674(00)81573-1","article-title":"A calcineurin-dependent transcriptional pathway for cardiac hypertrophy","volume":"93","author":"Molkentin","year":"1998","journal-title":"Cell"},{"key":"2021113010580712000_B37","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1126\/science.275.5308.1930","article-title":"Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3","volume":"275","author":"Beals","year":"1997","journal-title":"Science"},{"issue":"Suppl. 1","key":"2021113010580712000_B38","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1038\/sj.bjp.0707659","article-title":"Glycogen synthanse kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis","volume":"153","author":"Sugden","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"2021113010580712000_B39","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.peptides.2012.03.022","article-title":"The cardiac expression of Mas receptor is responsive to different physiological and pathological stimuli","volume":"35","author":"Dias-Peixoto","year":"2012","journal-title":"Peptides"},{"key":"2021113010580712000_B40","first-page":"589","article-title":"Selective increase of angiotensin-(1-7) and its receptor in hearts of spontaneously hypertensive rats subjected to physical training","volume":"93","author":"Filho","year":"2008","journal-title":"Exp. Physiol."},{"key":"2021113010580712000_B41","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1590\/S0100-879X2004000800017","article-title":"Enhanced expression of Ang-(1-7) during pregnancy","volume":"37","author":"Bronsnilhan","year":"2004","journal-title":"Braz. J. Med. Biol. Res."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/132\/11\/1117\/449479\/cs-2017-1606.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/132\/11\/1117\/449479\/cs-2017-1606.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T11:49:59Z","timestamp":1638272999000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/132\/11\/1117\/71975\/Angiotensin-1-7-reduces-cardiac-effects-of-thyroid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,5]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,6,14]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20171606","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,5]]}}}